Cargando…
Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer
OBJECTIVE: Optimal approaches to patients with local recurrence of rectal cancer are unclear in China. This study aimed to evaluaty -30te the clinical outcomes and toxicity associated with different treatment regimens for patients with local recurrence of rectal cancer. METHODS: A retrospective char...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721123/ https://www.ncbi.nlm.nih.gov/pubmed/33299348 http://dx.doi.org/10.2147/CMAR.S278427 |
_version_ | 1783619978743775232 |
---|---|
author | Tang, Zhongzhu Liu, Luying Liu, Dong Wu, Lie Lu, Ke Zhou, Ning Shen, Jinwen Chen, Guiping Liu, Guan |
author_facet | Tang, Zhongzhu Liu, Luying Liu, Dong Wu, Lie Lu, Ke Zhou, Ning Shen, Jinwen Chen, Guiping Liu, Guan |
author_sort | Tang, Zhongzhu |
collection | PubMed |
description | OBJECTIVE: Optimal approaches to patients with local recurrence of rectal cancer are unclear in China. This study aimed to evaluaty -30te the clinical outcomes and toxicity associated with different treatment regimens for patients with local recurrence of rectal cancer. METHODS: A retrospective chart review of patients with local recurrence of rectal cancer and previous radical surgical treatment between March 2010 and December 2017 with curative intent was performed. Disease-related endpoints included treatment progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method. Toxicities were assessed using Common Terminology Criteria for Adverse Events, version 5.0, and complications were scored according to the Clavien-Dindo classification. RESULTS: A total of 71 patients met the inclusion criteria in this study. The recurrence sites were mainly local recurrence in the pelvic cavity and regional lymph node metastasis. Twenty patients received chemoradiotherapy combined with surgery, 10 underwent surgery alone, and others received chemoradiotherapy-alone (n = 27) and chemotherapy-alone (n = 14) treatment. A clear difference was found in PFS between surgery/chemoradiotherapy with surgery and chemoradiotherapy/chemotherapy groups (26.6 months vs 14.1 months, P = 0.033). The PFS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 65.2 months, 20.2 months, and 14.2 months, respectively (P = 0.042). The multivariate analysis of PFS demonstrated that surgery was an independent factor. The proportion of patients with distant metastases after chemoradiotherapy/chemotherapy was higher than that of patients undergoing surgery (36.6% vs 21.4%, P = 0.179). The OS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 89.4 months, 66.0 months, and 62.8 months, respectively (P = 0.189). Radiation treatment and surgery did not increase extra severe toxicities. CONCLUSION: Surgery combined with chemoradiotherapy was a beneficial treatment mode for managing patients with locally recurrent, nonmetastatic rectal cancer. It was associated with better local disease control, no increase in toxicity, and prolonged survival among patients with locally recurrent rectal cancer. |
format | Online Article Text |
id | pubmed-7721123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77211232020-12-08 Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer Tang, Zhongzhu Liu, Luying Liu, Dong Wu, Lie Lu, Ke Zhou, Ning Shen, Jinwen Chen, Guiping Liu, Guan Cancer Manag Res Original Research OBJECTIVE: Optimal approaches to patients with local recurrence of rectal cancer are unclear in China. This study aimed to evaluaty -30te the clinical outcomes and toxicity associated with different treatment regimens for patients with local recurrence of rectal cancer. METHODS: A retrospective chart review of patients with local recurrence of rectal cancer and previous radical surgical treatment between March 2010 and December 2017 with curative intent was performed. Disease-related endpoints included treatment progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method. Toxicities were assessed using Common Terminology Criteria for Adverse Events, version 5.0, and complications were scored according to the Clavien-Dindo classification. RESULTS: A total of 71 patients met the inclusion criteria in this study. The recurrence sites were mainly local recurrence in the pelvic cavity and regional lymph node metastasis. Twenty patients received chemoradiotherapy combined with surgery, 10 underwent surgery alone, and others received chemoradiotherapy-alone (n = 27) and chemotherapy-alone (n = 14) treatment. A clear difference was found in PFS between surgery/chemoradiotherapy with surgery and chemoradiotherapy/chemotherapy groups (26.6 months vs 14.1 months, P = 0.033). The PFS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 65.2 months, 20.2 months, and 14.2 months, respectively (P = 0.042). The multivariate analysis of PFS demonstrated that surgery was an independent factor. The proportion of patients with distant metastases after chemoradiotherapy/chemotherapy was higher than that of patients undergoing surgery (36.6% vs 21.4%, P = 0.179). The OS of patients in the surgery combined with chemoradiotherapy, surgery alone, and chemotherapy/chemoradiotherapy groups was 89.4 months, 66.0 months, and 62.8 months, respectively (P = 0.189). Radiation treatment and surgery did not increase extra severe toxicities. CONCLUSION: Surgery combined with chemoradiotherapy was a beneficial treatment mode for managing patients with locally recurrent, nonmetastatic rectal cancer. It was associated with better local disease control, no increase in toxicity, and prolonged survival among patients with locally recurrent rectal cancer. Dove 2020-11-30 /pmc/articles/PMC7721123/ /pubmed/33299348 http://dx.doi.org/10.2147/CMAR.S278427 Text en © 2020 Tang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Tang, Zhongzhu Liu, Luying Liu, Dong Wu, Lie Lu, Ke Zhou, Ning Shen, Jinwen Chen, Guiping Liu, Guan Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer |
title | Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer |
title_full | Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer |
title_fullStr | Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer |
title_full_unstemmed | Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer |
title_short | Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer |
title_sort | clinical outcomes and safety of different treatment modes for local recurrence of rectal cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721123/ https://www.ncbi.nlm.nih.gov/pubmed/33299348 http://dx.doi.org/10.2147/CMAR.S278427 |
work_keys_str_mv | AT tangzhongzhu clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT liuluying clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT liudong clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT wulie clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT luke clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT zhouning clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT shenjinwen clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT chenguiping clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer AT liuguan clinicaloutcomesandsafetyofdifferenttreatmentmodesforlocalrecurrenceofrectalcancer |